– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated patient population – – Initiation of a combination trial of ARV-471 and Ibrance® (palbociclib) expected